Neoadjuvant Keytruda leads to pathological complete response rate of 60% in Phase Ib for TNBC

Merck & Co. Inc. (NYSE:MRK) said PD-1 inhibitor Keytruda pembrolizumab plus chemotherapy as neoadjuvant treatment of triple-negative breast

Read the full 182 word article

User Sign In